Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce ...
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
It also has another pill, amycretin ... said it expects CagriSema and amycretin to achieve better weight loss results than Wegovy. Lilly is also developing the GIP/GLP-1/glucagon receptor ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by ...
Oral GLP-1 drug in study led to average weight loss of 8.2% in a month at a 100 ... NOVO.B) and Eli Lilly (LLY), although the existing drugs on the market have to be injected rather than taken ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback